Amylyx pharmaceuticals, inc.AMLX.US Overview

US StockHealthcare

(No presentation for AMLX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

AMLX Overall Performance

AMLX AI Analysis & Strategy

AMLX Recent Performance

3.12%

Amylyx pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

AMLX PowerScanner

AMLX Key Information

AMLX Valuation Metrics

AMLX Earnings Table

AMLX Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.